CEO Thane Wettig said the quarter’s focus remained on “consistent progress we have made across our portfolio,” highlighting “FG-3246, our potential first-in-class antibody drug conjugate targeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results